APO Research
Talk to an analyst

APO RESEARCH · REPORT

Monoclonal Antibody VEGF Inhibitors

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Monoclonal Antibody VEGF Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

27 December 2025196 pages

Choose your research edition.

Industry ResearchMonoclonal Antibody VEGF Inhibitors Industry Research Report 2026127 pages · $2,950 USDIndustry Growth & TrendsGlobal Monoclonal Antibody VEGF Inhibitors Industry Growth and Trends Forecast to 2032107 pages · $3,450 USDMarket StructureGlobal Monoclonal Antibody VEGF Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Monoclonal Antibody VEGF Inhibitors Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Monoclonal Antibody VEGF Inhibitors Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Monoclonal Antibody VEGF Inhibitors market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Monoclonal Antibody VEGF Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Monoclonal Antibody VEGF Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Monoclonal Antibody VEGF Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Monoclonal Antibody VEGF Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Monoclonal Antibody VEGF Inhibitors include Amgen, Amneal Pharmaceuticals,, Celltrion Healthcare, Coherus BioSciences, Eli Lilly, Novartis, Pfizer, Roche and Boan Biotech, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Monoclonal Antibody VEGF Inhibitors market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Monoclonal Antibody VEGF Inhibitors and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Monoclonal Antibody VEGF Inhibitors sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Monoclonal Antibody VEGF Inhibitors market size, projected growth trends, production technologies, key applications, and end-use industries.

Monoclonal Antibody VEGF Inhibitors Segment by Company

Amgen

Amneal Pharmaceuticals,

Celltrion Healthcare

Coherus BioSciences

Eli Lilly

Novartis

Pfizer

Roche

Boan Biotech

Jiangsu Hengrui Pharmaceuticals

Qilu Pharma

SinoCellTech

Innovent

Chia Tai Tianqing

Monoclonal Antibody VEGF Inhibitors Segment by Type

Bevacizumab

Brolucizumab

Faricimab

Ramucirumab

Ranibizumab

Other

Monoclonal Antibody VEGF Inhibitors Segment by Application

Degenerative Eye Diseases

Cancer

Other

Monoclonal Antibody VEGF Inhibitors Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Monoclonal Antibody VEGF Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Monoclonal Antibody VEGF Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Monoclonal Antibody VEGF Inhibitors.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Monoclonal Antibody VEGF Inhibitors market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Monoclonal Antibody VEGF Inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Monoclonal Antibody VEGF Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Monoclonal Antibody VEGF Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Monoclonal Antibody VEGF Inhibitors Industry Trends Table 2. Monoclonal Antibody VEGF Inhibitors Industry Drivers Table 3. Monoclonal Antibody VEGF Inhibitors Industry Opportunities and Challenges Table 4. Monoclonal Antibody VEGF Inhibitors Industry Restraints Table 5. Global Monoclonal Antibody VEGF Inhibitors Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Monoclonal Antibody VEGF Inhibitors Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Monoclonal Antibody VEGF Inhibitors Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Monoclonal Antibody VEGF Inhibitors Sales Market Share by Manufacturers Table 9. Global Monoclonal Antibody VEGF Inhibitors Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Monoclonal Antibody VEGF Inhibitors Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Monoclonal Antibody VEGF Inhibitors Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Monoclonal Antibody VEGF Inhibitors Manufacturers, Product Type & Application Table 13. Global Monoclonal Antibody VEGF Inhibitors Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Monoclonal Antibody VEGF Inhibitors by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Bevacizumab Table 17. Major Manufacturers of Brolucizumab Table 18. Major Manufacturers of Faricimab Table 19. Major Manufacturers of Ramucirumab Table 20. Major Manufacturers of Ranibizumab Table 21. Major Manufacturers of Other Table 22. Global Monoclonal Antibody VEGF Inhibitors Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 23. Global Monoclonal Antibody VEGF Inhibitors Sales by Type (2021-2026) & (K Units) Table 24. Global Monoclonal Antibody VEGF Inhibitors Sales by Type (2027-2032) & (K Units) Table 25. Global Monoclonal Antibody VEGF Inhibitors Sales Market Share by Type (2021-2026) Table 26. Global Monoclonal Antibody VEGF Inhibitors Sales Market Share by Type (2027-2032) Table 27. Global Monoclonal Antibody VEGF Inhibitors Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 28. Global Monoclonal Antibody VEGF Inhibitors Revenue by Type (2021-2026) & (K Units) Table 29. Global Monoclonal Antibody VEGF Inhibitors Revenue by Type (2027-2032) & (K Units) Table 30. Global Monoclonal Antibody VEGF Inhibitors Revenue Market Share by Type (2021-2026) Table 31. Global Monoclonal Antibody VEGF Inhibitors Revenue Market Share by Type (2027-2032) Table 32. Major Manufacturers of Degenerative Eye Diseases Table 33. Major Manufacturers of Cancer Table 34. Major Manufacturers of Other Table 35. Global Monoclonal Antibody VEGF Inhibitors Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 36. Global Monoclonal Antibody VEGF Inhibitors Sales by Application (2021-2026) & (K Units) Table 37. Global Monoclonal Antibody VEGF Inhibitors Sales by Application (2027-2032) & (K Units) Table 38. Global Monoclonal Antibody VEGF Inhibitors Sales Market Share by Application (2021-2026) Table 39. Global Monoclonal Antibody VEGF Inhibitors Sales Market Share by Application (2027-2032) Table 40. Global Monoclonal Antibody VEGF Inhibitors Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 41. Global Monoclonal Antibody VEGF Inhibitors Revenue by Application (2021-2026) & (K Units) Table 42. Global Monoclonal Antibody VEGF Inhibitors Revenue by Application (2027-2032) & (K Units) Table 43. Global Monoclonal Antibody VEGF Inhibitors Revenue Market Share by Application (2021-2026) Table 44. Global Monoclonal Antibody VEGF Inhibitors Revenue Market Share by Application (2027-2032) Table 45. Global Monoclonal Antibody VEGF Inhibitors Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 46. Global Monoclonal Antibody VEGF Inhibitors Sales by Region (2021-2026) & (K Units) Table 47. Global Monoclonal Antibody VEGF Inhibitors Sales Market Share by Region (2021-2026) Table 48. Global Monoclonal Antibody VEGF Inhibitors Sales Forecasted by Region (2027-2032) & (K Units) Table 49. Global Monoclonal Antibody VEGF Inhibitors Sales Forecasted Market Share by Region (2027-2032) Table 50. North America Monoclonal Antibody VEGF Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 51. North America Monoclonal Antibody VEGF Inhibitors Sales by Country (2021-2026) & (K Units) Table 52. North America Monoclonal Antibody VEGF Inhibitors Sales by Country (2027-2032) & (K Units) Table 53. Europe Monoclonal Antibody VEGF Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. Europe Monoclonal Antibody VEGF Inhibitors Sales by Country (2021-2026) & (K Units) Table 55. Europe Monoclonal Antibody VEGF Inhibitors Sales by Country (2027-2032) & (K Units) Table 56. Asia Pacific Monoclonal Antibody VEGF Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. Asia Pacific Monoclonal Antibody VEGF Inhibitors Sales by Country (2021-2026) & (K Units) Table 58. Asia Pacific Monoclonal Antibody VEGF Inhibitors Sales by Country (2027-2032) & (K Units) Table 59. South America, Middle East and Africa Monoclonal Antibody VEGF Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 60. South America, Middle East and Africa Monoclonal Antibody VEGF Inhibitors Sales by Country (2021-2026) & (K Units) Table 61. South America, Middle East and Africa Monoclonal Antibody VEGF Inhibitors Sales by Country (2027-2032) & (K Units) Table 62. Global Monoclonal Antibody VEGF Inhibitors Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 63. Global Monoclonal Antibody VEGF Inhibitors Revenue by Region (2021-2026) & (US$ Million) Table 64. Global Monoclonal Antibody VEGF Inhibitors Revenue by Region (2027-2032) & (US$ Million) Table 65. Global Monoclonal Antibody VEGF Inhibitors Revenue Market Share by Region (2021-2026) Table 66. Global Monoclonal Antibody VEGF Inhibitors Revenue Market Share by Region (2027-2032) Table 67. Amgen Company Information Table 68. Amgen Business Overview Table 69. Amgen Monoclonal Antibody VEGF Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Amgen Monoclonal Antibody VEGF Inhibitors Product Portfolio Table 71. Amgen Recent Development Table 72. Amneal Pharmaceuticals, Company Information Table 73. Amneal Pharmaceuticals, Business Overview Table 74. Amneal Pharmaceuticals, Monoclonal Antibody VEGF Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Amneal Pharmaceuticals, Monoclonal Antibody VEGF Inhibitors Product Portfolio Table 76. Amneal Pharmaceuticals, Recent Development Table 77. Celltrion Healthcare Company Information Table 78. Celltrion Healthcare Business Overview Table 79. Celltrion Healthcare Monoclonal Antibody VEGF Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Celltrion Healthcare Monoclonal Antibody VEGF Inhibitors Product Portfolio Table 81. Celltrion Healthcare Recent Development Table 82. Coherus BioSciences Company Information Table 83. Coherus BioSciences Business Overview Table 84. Coherus BioSciences Monoclonal Antibody VEGF Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Coherus BioSciences Monoclonal Antibody VEGF Inhibitors Product Portfolio Table 86. Coherus BioSciences Recent Development Table 87. Eli Lilly Company Information Table 88. Eli Lilly Business Overview Table 89. Eli Lilly Monoclonal Antibody VEGF Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Eli Lilly Monoclonal Antibody VEGF Inhibitors Product Portfolio Table 91. Eli Lilly Recent Development Table 92. Novartis Company Information Table 93. Novartis Business Overview Table 94. Novartis Monoclonal Antibody VEGF Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 95. Novartis Monoclonal Antibody VEGF Inhibitors Product Portfolio Table 96. Novartis Recent Development Table 97. Pfizer Company Information Table 98. Pfizer Business Overview Table 99. Pfizer Monoclonal Antibody VEGF Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 100. Pfizer Monoclonal Antibody VEGF Inhibitors Product Portfolio Table 101. Pfizer Recent Development Table 102. Roche Company Information Table 103. Roche Business Overview Table 104. Roche Monoclonal Antibody VEGF Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 105. Roche Monoclonal Antibody VEGF Inhibitors Product Portfolio Table 106. Roche Recent Development Table 107. Boan Biotech Company Information Table 108. Boan Biotech Business Overview Table 109. Boan Biotech Monoclonal Antibody VEGF Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 110. Boan Biotech Monoclonal Antibody VEGF Inhibitors Product Portfolio Table 111. Boan Biotech Recent Development Table 112. Jiangsu Hengrui Pharmaceuticals Company Information Table 113. Jiangsu Hengrui Pharmaceuticals Business Overview Table 114. Jiangsu Hengrui Pharmaceuticals Monoclonal Antibody VEGF Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 115. Jiangsu Hengrui Pharmaceuticals Monoclonal Antibody VEGF Inhibitors Product Portfolio Table 116. Jiangsu Hengrui Pharmaceuticals Recent Development Table 117. Qilu Pharma Company Information Table 118. Qilu Pharma Business Overview Table 119. Qilu Pharma Monoclonal Antibody VEGF Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 120. Qilu Pharma Monoclonal Antibody VEGF Inhibitors Product Portfolio Table 121. Qilu Pharma Recent Development Table 122. SinoCellTech Company Information Table 123. SinoCellTech Business Overview Table 124. SinoCellTech Monoclonal Antibody VEGF Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 125. SinoCellTech Monoclonal Antibody VEGF Inhibitors Product Portfolio Table 126. SinoCellTech Recent Development Table 127. Innovent Company Information Table 128. Innovent Business Overview Table 129. Innovent Monoclonal Antibody VEGF Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 130. Innovent Monoclonal Antibody VEGF Inhibitors Product Portfolio Table 131. Innovent Recent Development Table 132. Chia Tai Tianqing Company Information Table 133. Chia Tai Tianqing Business Overview Table 134. Chia Tai Tianqing Monoclonal Antibody VEGF Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 135. Chia Tai Tianqing Monoclonal Antibody VEGF Inhibitors Product Portfolio Table 136. Chia Tai Tianqing Recent Development Table 137. Key Raw Materials Table 138. Raw Materials Key Suppliers Table 139. Monoclonal Antibody VEGF Inhibitors Distributors List Table 140. Monoclonal Antibody VEGF Inhibitors Customers List Table 141. Research Programs/Design for This Report Table 142. Authors List of This Report Table 143. Secondary Sources Table 144. Primary Sources List of Figures Figure 1. Monoclonal Antibody VEGF Inhibitors Product Image Figure 2. Global Monoclonal Antibody VEGF Inhibitors Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Monoclonal Antibody VEGF Inhibitors Market Size (2021-2032) & (US$ Million) Figure 4. Global Monoclonal Antibody VEGF Inhibitors Sales (2021-2032) & (K Units) Figure 5. Global Monoclonal Antibody VEGF Inhibitors Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Monoclonal Antibody VEGF Inhibitors Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Bevacizumab Image Figure 9. Brolucizumab Image Figure 10. Faricimab Image Figure 11. Ramucirumab Image Figure 12. Ranibizumab Image Figure 13. Other Image Figure 14. Global Monoclonal Antibody VEGF Inhibitors Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global Monoclonal Antibody VEGF Inhibitors Sales Market Share 2021 VS 2025 VS 2032 Figure 16. Global Monoclonal Antibody VEGF Inhibitors Sales Market Share by Type (2021-2032) Figure 17. Global Monoclonal Antibody VEGF Inhibitors Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 18. Global Monoclonal Antibody VEGF Inhibitors Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Monoclonal Antibody VEGF Inhibitors Revenue Market Share by Type (2021-2032) Figure 20. Degenerative Eye Diseases Image Figure 21. Cancer Image Figure 22. Other Image Figure 23. Global Monoclonal Antibody VEGF Inhibitors Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global Monoclonal Antibody VEGF Inhibitors Sales Market Share 2021 VS 2025 VS 2032 Figure 25. Global Monoclonal Antibody VEGF Inhibitors Sales Market Share by Application (2021-2032) Figure 26. Global Monoclonal Antibody VEGF Inhibitors Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 27. Global Monoclonal Antibody VEGF Inhibitors Revenue Market Share 2021 VS 2025 VS 2032 Figure 28. Global Monoclonal Antibody VEGF Inhibitors Revenue Market Share by Application (2021-2032) Figure 29. North America Monoclonal Antibody VEGF Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 30. North America Monoclonal Antibody VEGF Inhibitors Sales Market Share by Country (2021-2032) Figure 31. U.S. Monoclonal Antibody VEGF Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Canada Monoclonal Antibody VEGF Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Mexico Monoclonal Antibody VEGF Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Europe Monoclonal Antibody VEGF Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Europe Monoclonal Antibody VEGF Inhibitors Sales Market Share by Country (2021-2032) Figure 36. Germany Monoclonal Antibody VEGF Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 37. France Monoclonal Antibody VEGF Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 38. U.K. Monoclonal Antibody VEGF Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Italy Monoclonal Antibody VEGF Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Netherlands Monoclonal Antibody VEGF Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Asia Pacific Monoclonal Antibody VEGF Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Asia Pacific Monoclonal Antibody VEGF Inhibitors Sales Market Share by Country (2021-2032) Figure 43. China Monoclonal Antibody VEGF Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Japan Monoclonal Antibody VEGF Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 45. South Korea Monoclonal Antibody VEGF Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 46. Southeast Asia Monoclonal Antibody VEGF Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 47. India Monoclonal Antibody VEGF Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 48. Australia Monoclonal Antibody VEGF Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South America, Middle East and Africa Monoclonal Antibody VEGF Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 50. South America, Middle East and Africa Monoclonal Antibody VEGF Inhibitors Sales Market Share by Country (2021-2032) Figure 51. Brazil Monoclonal Antibody VEGF Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 52. South Africa Monoclonal Antibody VEGF Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Saudi Arabia Monoclonal Antibody VEGF Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Turkey Monoclonal Antibody VEGF Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Argentina Monoclonal Antibody VEGF Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 56. UAE Monoclonal Antibody VEGF Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Egypt Monoclonal Antibody VEGF Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Chile Monoclonal Antibody VEGF Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 59. Global Monoclonal Antibody VEGF Inhibitors Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Global Monoclonal Antibody VEGF Inhibitors Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 61. North America Monoclonal Antibody VEGF Inhibitors Revenue (2021-2032) & (US$ Million) Figure 62. North America Monoclonal Antibody VEGF Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Europe Monoclonal Antibody VEGF Inhibitors Revenue (2021-2032) & (US$ Million) Figure 64. Europe Monoclonal Antibody VEGF Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Asia-Pacific Monoclonal Antibody VEGF Inhibitors Revenue (2021-2032) & (US$ Million) Figure 66. Asia-Pacific Monoclonal Antibody VEGF Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. South America, Middle East and Africa Monoclonal Antibody VEGF Inhibitors Revenue (2021-2032) & (US$ Million) Figure 68. South America, Middle East and Africa Monoclonal Antibody VEGF Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 69. Monoclonal Antibody VEGF Inhibitors Value Chain Figure 70. Manufacturing Cost Structure Figure 71. Monoclonal Antibody VEGF Inhibitors Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • Bevacizumab
  • Brolucizumab
  • Faricimab
  • Ramucirumab
  • Ranibizumab
  • Other
Applications
  • Degenerative Eye Diseases
  • Cancer
  • Other
Companies covered
  • Amgen
  • Amneal Pharmaceuticals,
  • Celltrion Healthcare
  • Coherus BioSciences
  • Eli Lilly
  • Novartis
  • Pfizer
  • Roche
  • Boan Biotech
  • Jiangsu Hengrui Pharmaceuticals
  • Qilu Pharma
  • SinoCellTech
  • Innovent
  • Chia Tai Tianqing

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Monoclonal Antibody VEGF Inhibitors Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Monoclonal Antibody VEGF Inhibitors Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Monoclonal Antibody VEGF Inhibitors Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Monoclonal Antibody VEGF Inhibitors Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Monoclonal Antibody VEGF Inhibitors Market Dynamics
  1. 2.1 Monoclonal Antibody VEGF Inhibitors Industry Trends
  2. 2.2 Monoclonal Antibody VEGF Inhibitors Industry Drivers
  3. 2.3 Monoclonal Antibody VEGF Inhibitors Industry Opportunities and Challenges
  4. 2.4 Monoclonal Antibody VEGF Inhibitors Industry Restraints
3 Monoclonal Antibody VEGF Inhibitors Market by Manufacturers
  1. 3.1 Global Monoclonal Antibody VEGF Inhibitors Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Monoclonal Antibody VEGF Inhibitors Sales by Manufacturers (2021-2026)
  3. 3.3 Global Monoclonal Antibody VEGF Inhibitors Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Monoclonal Antibody VEGF Inhibitors Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Monoclonal Antibody VEGF Inhibitors Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Monoclonal Antibody VEGF Inhibitors Manufacturers, Product Type & Application
  7. 3.7 Global Monoclonal Antibody VEGF Inhibitors Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Monoclonal Antibody VEGF Inhibitors Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Monoclonal Antibody VEGF Inhibitors Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Monoclonal Antibody VEGF Inhibitors Tier 1, Tier 2, and Tier 3
4 Monoclonal Antibody VEGF Inhibitors Market by Type
  1. 4.1 Monoclonal Antibody VEGF Inhibitors Type Introduction
  2. 4.1.1 Bevacizumab
  3. 4.1.2 Brolucizumab
  4. 4.1.3 Faricimab
  5. 4.1.4 Ramucirumab
  6. 4.1.5 Ranibizumab
  7. 4.1.6 Other
  8. 4.2 Global Monoclonal Antibody VEGF Inhibitors Sales by Type
  9. 4.2.1 Global Monoclonal Antibody VEGF Inhibitors Sales by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Monoclonal Antibody VEGF Inhibitors Sales by Type (2021-2032)
  11. 4.2.3 Global Monoclonal Antibody VEGF Inhibitors Sales Market Share by Type (2021-2032)
  12. 4.3 Global Monoclonal Antibody VEGF Inhibitors Revenue by Type
  13. 4.3.1 Global Monoclonal Antibody VEGF Inhibitors Revenue by Type (2021 VS 2025 VS 2032)
  14. 4.3.2 Global Monoclonal Antibody VEGF Inhibitors Revenue by Type (2021-2032)
  15. 4.3.3 Global Monoclonal Antibody VEGF Inhibitors Revenue Market Share by Type (2021-2032)
5 Monoclonal Antibody VEGF Inhibitors Market by Application
  1. 5.1 Monoclonal Antibody VEGF Inhibitors Application Introduction
  2. 5.1.1 Degenerative Eye Diseases
  3. 5.1.2 Cancer
  4. 5.1.3 Other
  5. 5.2 Global Monoclonal Antibody VEGF Inhibitors Sales by Application
  6. 5.2.1 Global Monoclonal Antibody VEGF Inhibitors Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Monoclonal Antibody VEGF Inhibitors Sales by Application (2021-2032)
  8. 5.2.3 Global Monoclonal Antibody VEGF Inhibitors Sales Market Share by Application (2021-2032)
  9. 5.3 Global Monoclonal Antibody VEGF Inhibitors Revenue by Application
  10. 5.3.1 Global Monoclonal Antibody VEGF Inhibitors Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Monoclonal Antibody VEGF Inhibitors Revenue by Application (2021-2032)
  12. 5.3.3 Global Monoclonal Antibody VEGF Inhibitors Revenue Market Share by Application (2021-2032)
6 Global Monoclonal Antibody VEGF Inhibitors Sales by Region
  1. 6.1 Global Monoclonal Antibody VEGF Inhibitors Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Monoclonal Antibody VEGF Inhibitors Sales by Region (2021-2032)
  3. 6.2.1 Global Monoclonal Antibody VEGF Inhibitors Sales by Region (2021-2026)
  4. 6.2.2 Global Monoclonal Antibody VEGF Inhibitors Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Monoclonal Antibody VEGF Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Monoclonal Antibody VEGF Inhibitors Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Monoclonal Antibody VEGF Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Monoclonal Antibody VEGF Inhibitors Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Monoclonal Antibody VEGF Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Monoclonal Antibody VEGF Inhibitors Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Monoclonal Antibody VEGF Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Monoclonal Antibody VEGF Inhibitors Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Monoclonal Antibody VEGF Inhibitors Revenue by Region
  1. 7.1 Global Monoclonal Antibody VEGF Inhibitors Revenue by Region
  2. 7.1.1 Global Monoclonal Antibody VEGF Inhibitors Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Monoclonal Antibody VEGF Inhibitors Revenue by Region (2021-2026)
  4. 7.1.3 Global Monoclonal Antibody VEGF Inhibitors Revenue by Region (2027-2032)
  5. 7.1.4 Global Monoclonal Antibody VEGF Inhibitors Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Monoclonal Antibody VEGF Inhibitors Revenue (2021-2032)
  8. 7.2.2 North America Monoclonal Antibody VEGF Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Monoclonal Antibody VEGF Inhibitors Revenue (2021-2032)
  11. 7.3.2 Europe Monoclonal Antibody VEGF Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Monoclonal Antibody VEGF Inhibitors Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Monoclonal Antibody VEGF Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Monoclonal Antibody VEGF Inhibitors Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Monoclonal Antibody VEGF Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Amgen
  2. 8.1.1 Amgen Company Information
  3. 8.1.2 Amgen Business Overview
  4. 8.1.3 Amgen Monoclonal Antibody VEGF Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Amgen Monoclonal Antibody VEGF Inhibitors Product Portfolio
  6. 8.1.5 Amgen Recent Developments
  7. 8.2 Amneal Pharmaceuticals,
  8. 8.2.1 Amneal Pharmaceuticals, Company Information
  9. 8.2.2 Amneal Pharmaceuticals, Business Overview
  10. 8.2.3 Amneal Pharmaceuticals, Monoclonal Antibody VEGF Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Amneal Pharmaceuticals, Monoclonal Antibody VEGF Inhibitors Product Portfolio
  12. 8.2.5 Amneal Pharmaceuticals, Recent Developments
  13. 8.3 Celltrion Healthcare
  14. 8.3.1 Celltrion Healthcare Company Information
  15. 8.3.2 Celltrion Healthcare Business Overview
  16. 8.3.3 Celltrion Healthcare Monoclonal Antibody VEGF Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Celltrion Healthcare Monoclonal Antibody VEGF Inhibitors Product Portfolio
  18. 8.3.5 Celltrion Healthcare Recent Developments
  19. 8.4 Coherus BioSciences
  20. 8.4.1 Coherus BioSciences Company Information
  21. 8.4.2 Coherus BioSciences Business Overview
  22. 8.4.3 Coherus BioSciences Monoclonal Antibody VEGF Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Coherus BioSciences Monoclonal Antibody VEGF Inhibitors Product Portfolio
  24. 8.4.5 Coherus BioSciences Recent Developments
  25. 8.5 Eli Lilly
  26. 8.5.1 Eli Lilly Company Information
  27. 8.5.2 Eli Lilly Business Overview
  28. 8.5.3 Eli Lilly Monoclonal Antibody VEGF Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Eli Lilly Monoclonal Antibody VEGF Inhibitors Product Portfolio
  30. 8.5.5 Eli Lilly Recent Developments
  31. 8.6 Novartis
  32. 8.6.1 Novartis Company Information
  33. 8.6.2 Novartis Business Overview
  34. 8.6.3 Novartis Monoclonal Antibody VEGF Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Novartis Monoclonal Antibody VEGF Inhibitors Product Portfolio
  36. 8.6.5 Novartis Recent Developments
  37. 8.7 Pfizer
  38. 8.7.1 Pfizer Company Information
  39. 8.7.2 Pfizer Business Overview
  40. 8.7.3 Pfizer Monoclonal Antibody VEGF Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Pfizer Monoclonal Antibody VEGF Inhibitors Product Portfolio
  42. 8.7.5 Pfizer Recent Developments
  43. 8.8 Roche
  44. 8.8.1 Roche Company Information
  45. 8.8.2 Roche Business Overview
  46. 8.8.3 Roche Monoclonal Antibody VEGF Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Roche Monoclonal Antibody VEGF Inhibitors Product Portfolio
  48. 8.8.5 Roche Recent Developments
  49. 8.9 Boan Biotech
  50. 8.9.1 Boan Biotech Company Information
  51. 8.9.2 Boan Biotech Business Overview
  52. 8.9.3 Boan Biotech Monoclonal Antibody VEGF Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Boan Biotech Monoclonal Antibody VEGF Inhibitors Product Portfolio
  54. 8.9.5 Boan Biotech Recent Developments
  55. 8.10 Jiangsu Hengrui Pharmaceuticals
  56. 8.10.1 Jiangsu Hengrui Pharmaceuticals Company Information
  57. 8.10.2 Jiangsu Hengrui Pharmaceuticals Business Overview
  58. 8.10.3 Jiangsu Hengrui Pharmaceuticals Monoclonal Antibody VEGF Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Jiangsu Hengrui Pharmaceuticals Monoclonal Antibody VEGF Inhibitors Product Portfolio
  60. 8.10.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
  61. 8.11 Qilu Pharma
  62. 8.11.1 Qilu Pharma Company Information
  63. 8.11.2 Qilu Pharma Business Overview
  64. 8.11.3 Qilu Pharma Monoclonal Antibody VEGF Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Qilu Pharma Monoclonal Antibody VEGF Inhibitors Product Portfolio
  66. 8.11.5 Qilu Pharma Recent Developments
  67. 8.12 SinoCellTech
  68. 8.12.1 SinoCellTech Company Information
  69. 8.12.2 SinoCellTech Business Overview
  70. 8.12.3 SinoCellTech Monoclonal Antibody VEGF Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 SinoCellTech Monoclonal Antibody VEGF Inhibitors Product Portfolio
  72. 8.12.5 SinoCellTech Recent Developments
  73. 8.13 Innovent
  74. 8.13.1 Innovent Company Information
  75. 8.13.2 Innovent Business Overview
  76. 8.13.3 Innovent Monoclonal Antibody VEGF Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Innovent Monoclonal Antibody VEGF Inhibitors Product Portfolio
  78. 8.13.5 Innovent Recent Developments
  79. 8.14 Chia Tai Tianqing
  80. 8.14.1 Chia Tai Tianqing Company Information
  81. 8.14.2 Chia Tai Tianqing Business Overview
  82. 8.14.3 Chia Tai Tianqing Monoclonal Antibody VEGF Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Chia Tai Tianqing Monoclonal Antibody VEGF Inhibitors Product Portfolio
  84. 8.14.5 Chia Tai Tianqing Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Monoclonal Antibody VEGF Inhibitors Value Chain Analysis
  2. 9.1.1 Monoclonal Antibody VEGF Inhibitors Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Monoclonal Antibody VEGF Inhibitors Production Mode & Process
  6. 9.2 Monoclonal Antibody VEGF Inhibitors Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Monoclonal Antibody VEGF Inhibitors Distributors
  9. 9.2.3 Monoclonal Antibody VEGF Inhibitors Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst